Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome
- 7 August 2010
- journal article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 29 (2) , 201-206
Abstract
Intriguing studies suggest that osteocalcin (OC) and its carboxylated (Gla)/uncarboxylated form are involved in the regulation of insulin secretion and action. Additionally, advanced glycated end products (AGEs) directly regulate the secretion of these osteoblast-derived molecules. In polycystic ovarian syndrome (PCOS), among the pathophysiological aberrations, deregulation of insulin secretion and action as well as elevated AGEs levels have been demonstrated. In this study, we evaluated the serum levels of osteocalcin and Gla osteocalcin and their possible associations with metabolic, hormonal, and ultrasonographic components of PSOS: 97 women were studied, 50 PCOS patients and 47 controls, matched for age and body mass index (BMI). In each subject, the levels of bone metabolism markers have been evaluated, and metabolic and hormonal profiles as well as ovarian ultrasound were carried out. Osteocalcin (4.30 ± 1.74 vs. 6.20 ± 1.78 ng/ml, P < 0.0005) values were significantly lower, whereas Gla osteocalcin (37.93 ± 6.87 vs. 9.64 ± 8.21 ng/ml, P < 0.0005) and receptor activator for nuclear factor-κB ligand (0.54 ± 0.26 vs. 0.16 ± 0.15 pmol/l, P < 0.0005) values were significantly higher in PCOS subjects compared to the control group, independently of obesity. A significant association was disclosed between osteocalcin and Gla osteocalcin with androgens, insulin resistance, AGEs, and ovarian morphology. Receiver operating curve analysis revealed that Gla osteocalcin [AUC, 0.975 (95% CI, 0.93–1.00)] as well as AGEs are significant prognostic factors of PCOS [AUC, 0.986 (95% CI, 0.97–1.00)]. Lower osteocalcin and elevated serum levels of its carboxylated form are displayed in PCOS subjects and are associated with several PCOS components. These findings suggest a potential interaction between bone-derived markers and the metabolic/hormonal abnormalities observed in PCOS. However, the pathophysiological mechanisms and moreover the possible clinical implications require further investigation.Keywords
This publication has 23 references indexed in Scilit:
- γ-Carboxylation of osteocalcin and insulin resistance in older men and womenThe American Journal of Clinical Nutrition, 2009
- In Skeletal Muscle Advanced Glycation End Products (AGEs) Inhibit Insulin Action and Induce the Formation of Multimolecular Complexes Including the Receptor for AGEsJournal of Biological Chemistry, 2008
- Relationship between osteocalcin and glucose metabolism in postmenopausal womenClinica Chimica Acta, 2008
- Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndromeEuropean Journal of Endocrinology, 2008
- Reciprocal regulation of bone and energy metabolismTrends in Endocrinology & Metabolism, 2008
- Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type miceProceedings of the National Academy of Sciences, 2008
- Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic CellsExperimental and Clinical Endocrinology & Diabetes, 2008
- Endocrine Regulation of Energy Metabolism by the SkeletonCell, 2007
- Serum Parathyroid Hormone Concentrations Are Increased in Women with Polycystic Ovary SyndromeClinical Chemistry, 2005
- Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral densityJournal of Bone and Mineral Metabolism, 2004